AnaptysBio, Inc. (ANAB)
48.28
-0.36
(-0.74%)
USD |
NASDAQ |
Oct 30, 16:00
48.29
+0.01
(+0.02%)
After-Hours: 20:00
AnaptysBio Enterprise Value : 1.541B for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 1.541B |
| October 29, 2026 | 1.551B |
| October 28, 2026 | 1.607B |
| October 27, 2026 | 1.581B |
| October 26, 2026 | 1.555B |
| October 23, 2026 | 1.554B |
| October 22, 2026 | 1.535B |
| October 21, 2026 | 1.531B |
| October 20, 2026 | 1.456B |
| October 19, 2026 | 1.569B |
| October 16, 2026 | 1.491B |
| October 15, 2026 | 1.553B |
| October 14, 2026 | 1.493B |
| October 13, 2026 | 1.461B |
| October 12, 2026 | 1.474B |
| October 09, 2026 | 1.471B |
| October 08, 2026 | 1.479B |
| October 07, 2026 | 1.463B |
| October 06, 2026 | 1.529B |
| October 05, 2026 | 1.568B |
| October 02, 2026 | 1.548B |
| October 01, 2026 | 1.551B |
| September 30, 2026 | 1.600B |
| September 29, 2026 | 1.603B |
| September 28, 2026 | 1.616B |
| Date | Value |
|---|---|
| September 25, 2026 | 1.622B |
| September 24, 2026 | 1.642B |
| September 23, 2026 | 1.615B |
| September 22, 2026 | 1.708B |
| September 21, 2026 | 1.738B |
| September 18, 2026 | 1.746B |
| September 17, 2026 | 1.742B |
| September 16, 2026 | 1.720B |
| September 15, 2026 | 1.731B |
| September 14, 2026 | 1.714B |
| September 11, 2026 | 1.707B |
| September 10, 2026 | 1.745B |
| September 09, 2026 | 1.761B |
| September 08, 2026 | 1.788B |
| September 04, 2026 | 1.794B |
| September 03, 2026 | 1.814B |
| September 02, 2026 | 1.765B |
| September 01, 2026 | 1.749B |
| August 31, 2026 | 1.801B |
| August 28, 2026 | 1.779B |
| August 27, 2026 | 1.809B |
| August 26, 2026 | 1.830B |
| August 25, 2026 | 1.841B |
| August 24, 2026 | 1.843B |
| August 21, 2026 | 1.822B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 556.15M |
| Amgen, Inc. | 295.24B |
| Anika Therapeutics, Inc. | 267.21M |
| BioCryst Pharmaceuticals, Inc. | 2.646B |
| Imunon, Inc. | 5.227M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 229.24M |
| Revenue (Quarterly) | 27.49M |
| Total Expenses (Quarterly) | -201.75M |
| EPS Diluted (Quarterly) | 6.185 |
| Earnings Yield | 13.35% |
| Operating Earnings Yield | 9.34% |
| Normalized Earnings Yield | 13.35 |